High-performance liquid chromatographic assays for the quantification of amikacin in human plasma and urine

Amikacin, an aminoglycoside antibiotic, is frequently coadministered with penicillins and broad-spectrum cephalosporins to synergize the activity of these agents. Sensitive, selective and reproducible high-performance liquid chromatographic assays have been developed for the quantification of amikac...

Full description

Saved in:
Bibliographic Details
Published in:Journal of chromatography. Biomedical applications 1992-02, Vol.574 (1), p.93-99
Main Authors: Papp, Eugene A., Knupp, Catherine A., Barbhaiya, Rashmi H.
Format: Article
Language:English
Subjects:
Antibacterial agents
Antibiotics. Antiinfectious agents. Antiparasitic agents
Biological and medical sciences
Chemistry
Chemistry, Analytical
Medical sciences
Pharmacology. Drug treatments
Physical Sciences
Science & Technology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Amikacin, an aminoglycoside antibiotic, is frequently coadministered with penicillins and broad-spectrum cephalosporins to synergize the activity of these agents. Sensitive, selective and reproducible high-performance liquid chromatographic assays have been developed for the quantification of amikacin in plasma and urine collected from human subjects. The plasma method involves the ultrafiltration of plasma prior to derivatization. An aliquot of plasma ultrafiltrate or urine is mixed with dimethyl sulfoxide and tris(hydroxymethyl)aminoethane followed by derivatization of amikacin with 1-fluoro-2,4-dinitrobenzene at 58°C for 30 min. The reaction mixture is then injected directly onto a reversed-phase C 18 column preceded by a guard column. The column is eluted with a mobile phase containing acetonitrile and 2-methoxyethanol in 1% Tris buffer. Amikacin derivative is detected at 340 nm. The methods were applied for the analysis of amikacin in plasma and urine samples from volunteers receiving amikacin and cefepime, a fourth-generation cephalosporin, in a clinical pharmacokinetic drug interaction study.
ISSN:0378-4347
DOI:10.1016/0378-4347(92)80102-V